Anatomical Sciences Journal

en Evaluation the effects of oncolytic Coxsackievirus A21 on the colorectal cancer mouse model Immunological Effects of Oncolytic Coxsackievirus A21 on the Mouse Model of Colorectal Cancer Stem Cell Stem Cell Original Original Introduction: According to numerous studies, colorectal cancer will probably become more common over the next few decades. This phenomenon causes by population growth, ageing, and rising rates of crucial risk factors from people's lifestyle, such as idleness and malnutrition. The approach of Surgery to remove malignancies is typically the first step of colon cancer treatment. There may also be a recommendation for additional therapies like chemotherapy and radiation therapy. However, there is always a need to develop novel cancer treatment strategies due to drug resistance and lack of targeted approaches. This study aimed to evaluate the effects of oncolytic Coxsackievirus A21 on the colorectal cancer mouse model. Methods: Colorectal cancer mouse modelling was carried out by injecting 5×106 CT-26 cells (a colonic carcinoma cell line) into the left flank of female BALB/c mice. After noticing the palpable tumor, proceed to treat them with oncolytic Coxsackievirus A21 (106 TCID50/ml, twice at one-week interval). The mice in each group were put to death ten days after the last therapy to assess the efficacy of the treatment. Results: The present study results demonstrated that treatment with Coxsackievirus A21 increased the level of NO production, LDH, and IFN-γ levels and significantly reduced the secretion of IL-4, IL-10, and TGF-β in compared with control group. Conclusion: In our mouse model of colorectal cancer, the Coxsackievirus A21 therapy encouraged favorable outcomes. The current study also showed that inducing innate anti-tumor immunity, which was more potent than that seen with monotherapy, and immune deviation from anti-inflammatory cytokines (like IL-4, IL-10, and TGF-β) to pro-inflammatory cytokine IFN-γ might contribute to the beneficial effects of the combination.   Introduction: Cancer is one of the most prevalent causes of death worldwide. In terms of global mortality, colorectal cancer (CRC) is the second most prevalent cancer form. Typically, the initial step in treating colon cancer is surgery to remove tumors. A referral for further treatments like chemotherapy and radiation therapy could also be made. However, because of medication resistance and a lack of focused treatments, it is constantly necessary to create new cancer therapy methods. This investigation examined the impact of the oncolytic coxsackievirus A21 (CVA21) on a mouse model of colorectal cancer. Methods: Thirty BALB/c mice were divided into three equal groups randomly. 5×106 CT-26 cells, a colonic carcinoma cell line, were injected into the left flank of each animal to simulate colorectal cancer. Group A was treated with PBS once the palpable tumor was discovered (18 days later), group B was treated with the oncolytic CVA21 (106 TCID50/mL, twice at one-week intervals), and group C was treated with 5-fluorouracil (5-FU), 50 mg/kg, twice at one-week interval. The mice were euthanized ten days after the final injection, and the spleens were removed and examined under sterile circumstances to determine the lymphocyte proliferation index, LDH, NO, IL-4, IL-10, IFN-γ, and TGFβ production levels. A significant P˂0.05 level was considered in all evaluations. Results: The current study’s findings showed that when compared to the control group, treatment with CVA21 increased NO (30.5±4.10 µM), LDH (58.18±4.61 %), and IFN-γ (44.82±3.72 pg/mL) levels and significantly decreased the secretion of IL-4 (30.07±3.34 pg/mL), IL-10 (62.11±5.69 pg/mL), and TGF-β (56.66±6.88 pg/mL). Conclusion: The CVA21 treatment for colorectal cancer appears to have some potential benefits. In other words, the study’s findings demonstrated that using oncolytic viruses also activates the innate immune system by raising levels of nitric oxide and the acquired immune system. The favorable benefits of the combination may also be attributable to immunological divergence in the current study from anti-inflammatory cytokines (such as IL-4, IL-10, and TGF-β) to pro-inflammatory cytokines, such as IFN-γ. Colorectal cancer, CT26 cell line, Oncolytic virus, Coxsackievirus A21, BALB/c Anti-tumor immunity, Colorectal cancer, CT26 cell line, Coxsackievirus A21, Oncolytic virus, Virotherapy 101 110 http://anatomyjournal.ir/browse.php?a_code=A-10-397-1&slc_lang=en&sid=1 Reza Karbalaee dr.reza313@gmail.com 10031947532846007317 10031947532846007317 Yes Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran. Morteza Izadi morteza_izadi@yahoo.com 10031947532846007318 10031947532846007318 No Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Bahman Jalali Kondori bahmanjalali2010@gmail.com 10031947532846007319 10031947532846007319 No Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran. Ruhollah Dorostkar r.dorost@yahoo.com 10031947532846007320 10031947532846007320 No Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Seyed Morteza Hosseini sm_hosseini@bmsu.ac.ir 10031947532846007321 10031947532846007321 No Medicine, Quran and Hadith Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Hadi Esmaeili Gouvarchin Ghaleh h.smaili69@yahoo.com 10031947532846007322 10031947532846007322 No Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.